A reappraisal of CTLA-4 checkpoint blockade in cancer immunotherapy

[1]  N. Agarwal,et al.  The future of immune checkpoint cancer therapy after PD-1 and CTLA-4. , 2017, Immunotherapy.

[2]  G. Gao,et al.  Remarkably similar CTLA-4 binding properties of therapeutic ipilimumab and tremelimumab antibodies , 2017, Oncotarget.

[3]  S. Almo,et al.  Structural basis for cancer immunotherapy by the first-in-class checkpoint inhibitor ipilimumab , 2017, Proceedings of the National Academy of Sciences.

[4]  R. Holmdahl,et al.  Induction of autoimmune disease by deletion of CTLA-4 in mice in adulthood , 2016, Proceedings of the National Academy of Sciences.

[5]  Xue Han,et al.  Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future. , 2015, The Journal of clinical investigation.

[6]  S. Young,et al.  A Transendocytosis Model of CTLA-4 Function Predicts Its Suppressive Behavior on Regulatory T Cells , 2015, The Journal of Immunology.

[7]  S. Ostrand-Rosenberg,et al.  A Soluble Form of CD80 Enhances Antitumor Immunity by Neutralizing Programmed Death Ligand-1 and Simultaneously Providing Costimulation , 2014, Cancer Immunology Research.

[8]  J. Wolchok,et al.  Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti–CTLA-4 therapy against melanoma , 2013, The Journal of experimental medicine.

[9]  G. Dranoff,et al.  Activating Fc γ receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies , 2013, The Journal of experimental medicine.

[10]  A. Korman,et al.  Anti-CTLA-4 Antibodies of IgG2a Isotype Enhance Antitumor Activity through Reduction of Intratumoral Regulatory T Cells , 2013, Cancer Immunology Research.

[11]  L. Walker,et al.  The emerging role of CTLA4 as a cell-extrinsic regulator of T cell responses , 2011, Nature Reviews Immunology.

[12]  G. Anderson,et al.  Trans-Endocytosis of CD80 and CD86: A Molecular Basis for the Cell-Extrinsic Function of CTLA-4 , 2011, Science.

[13]  D. Schadendorf,et al.  Improved survival with ipilimumab in patients with metastatic melanoma. , 2010, The New England journal of medicine.

[14]  A. D'amico,et al.  Dendritic cells in the thymus contribute to T-regulatory cell induction , 2008, Proceedings of the National Academy of Sciences.

[15]  T. Nomura,et al.  CTLA-4 Control over Foxp3+ Regulatory T Cell Function , 2008, Science.

[16]  J. Allison,et al.  Checkpoint blockade in cancer immunotherapy. , 2007, Advances in immunology.

[17]  G. Feng,et al.  Conditional Deletion of Shp2 Tyrosine Phosphatase in Thymocytes Suppresses Both Pre-TCR and TCR Signals1 , 2006, The Journal of Immunology.

[18]  D. Jarjoura,et al.  Combination therapy with anti-CTL antigen-4 and anti-4-1BB antibodies enhances cancer immunity and reduces autoimmunity. , 2006, Cancer research.

[19]  M. Caligiuri,et al.  Human CTLA4 knock-in mice unravel the quantitative link between tumor immunity and autoimmunity induced by anti-CTLA-4 antibodies. , 2005, Blood.

[20]  M. Caligiuri,et al.  Anti-human CTLA-4 monoclonal antibody promotes T-cell expansion and immunity in a hu-PBL-SCID model: a new method for preclinical screening of costimulatory monoclonal antibodies. , 2005, Blood.

[21]  B. Hock,et al.  Identification of a Circulating Soluble Form of CD80: Levels in Patients with Hematological Malignancies , 2004, Leukemia & lymphoma.

[22]  A. Korman,et al.  Activity and Safety of CTLA-4 Blockade Combined with Vaccines in Cynomolgus Macaques , 2003, The Journal of Immunology.

[23]  Thomas A. Davis,et al.  Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[24]  Ping Lu,et al.  B7H Costimulates Clonal Expansion of, and Cognate Destruction of Tumor Cells by, CD8+ T Lymphocytes In Vivo , 2001, The Journal of experimental medicine.

[25]  A. Fedorov,et al.  Structural basis for co-stimulation by the human CTLA-4/B7-2 complex , 2001, Nature.

[26]  Yan Zhang,et al.  Crystal structure of the B7-1/CTLA-4 complex that inhibits human immune responses , 2001, Nature.

[27]  M. Bachmann,et al.  Normal pathogen‐specific immune responses mounted by CTLA‐4‐deficient T cells: a paradigm reconsidered , 2001, European journal of immunology.

[28]  T. Mak,et al.  Cutting edge: lymphoproliferative disease in the absence of CTLA-4 is not T cell autonomous. , 1999, Journal of immunology.

[29]  J. Bluestone,et al.  Molecular basis of T cell inactivation by CTLA-4. , 1998, Science.

[30]  J. Bluestone,et al.  Realization of the therapeutic potential of CTLA-4 blockade in low-dose chemotherapy-treated tumor-bearing mice. , 1998, Cancer research.

[31]  K. Bennett,et al.  Interaction of the cytoplasmic tail of CTLA-4 (CD152) with a clathrin-associated protein is negatively regulated by tyrosine phosphorylation. , 1997, Biochemistry.

[32]  Y. Liu,et al.  Is CTLA-4 a negative regulator for T-cell activation? , 1997, Immunology today.

[33]  A. Singer,et al.  T Cell Receptor (TCR)-induced Death of Immature CD4+CD8+ Thymocytes by Two Distinct Mechanisms Differing in Their Requirement for CD28 Costimulation: Implications for Negative Selection in the Thymus , 1997, The Journal of experimental medicine.

[34]  M. V. Vander Heiden,et al.  Interaction of CTLA-4 with the clathrin-associated protein AP50 results in ligand-independent endocytosis that limits cell surface expression. , 1997, Journal of immunology.

[35]  Yan Wu,et al.  CTLA-4–B7 Interaction Is Sufficient to Costimulate T Cell Clonal Expansion , 1997, The Journal of experimental medicine.

[36]  E. Simpson,et al.  B7-1 and B7-2 have overlapping, critical roles in immunoglobulin class switching and germinal center formation. , 1997, Immunity.

[37]  K. Bennett,et al.  Intracellular trafficking of CTLA-4 and focal localization towards sites of TCR engagement. , 1996, Immunity.

[38]  T. Mak,et al.  Regulation of T Cell Receptor Signaling by Tyrosine Phosphatase SYP Association with CTLA-4 , 1996, Science.

[39]  J. Allison,et al.  Enhancement of Antitumor Immunity by CTLA-4 Blockade , 1996, Science.

[40]  H. Griesser,et al.  Lymphoproliferative Disorders with Early Lethality in Mice Deficient in Ctla-4 , 1995, Science.

[41]  J. Bluestone,et al.  Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. , 1995, Immunity.

[42]  J. Allison,et al.  CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation , 1995, The Journal of experimental medicine.

[43]  P. Linsley,et al.  Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors. , 1994, Immunity.

[44]  P. Linsley,et al.  CTLA-4 can function as a negative regulator of T cell activation. , 1994, Immunity.

[45]  Y. Wu,et al.  T cell costimulation by B7/BB1 induces CD8 T cell-dependent tumor rejection: an important role of B7/BB1 in the induction, recruitment, and effector function of antitumor T cells , 1994, The Journal of experimental medicine.

[46]  A. Singer,et al.  Negative selection of CD4+CD8+ thymocytes by T cell receptor-induced apoptosis requires a costimulatory signal that can be provided by CD28 , 1994, The Journal of experimental medicine.

[47]  J. Gribben,et al.  Murine B7-2, an alternative CTLA4 counter-receptor that costimulates T cell proliferation and interleukin 2 production , 1993, The Journal of experimental medicine.

[48]  Y. Wu,et al.  A major costimulatory molecule on antigen-presenting cells, CTLA4 ligand A, is distinct from B7 , 1993, The Journal of experimental medicine.

[49]  C. Janeway,et al.  Co‐stimulation of murine CD4 T cell growth: cooperation between B7 and heat‐stable antigen , 1992, European journal of immunology.

[50]  P. Linsley,et al.  CTLA-4 is a second receptor for the B cell activation antigen B7 , 1991, The Journal of experimental medicine.